咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Recent advances in vaccination... 收藏

Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine

Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine

作     者:Saqib Walayat Zohair Ahmed Daniel Martin Srinivas Puli Michael Cashman Sonu Dhillon 

作者机构:Department of Gastroenterology andHepatologyUniversity of Illinois PeoriaCampusOSF Saint Francis Medical Center Department of Internal MedicineUniversityof Illinois Peoria CampusOSF Saint Francis Medical Center 

出 版 物:《World Journal of Hepatology》 (世界肝病学杂志(英文版)(电子版))

年 卷 期:2015年第7卷第24期

页      面:2503-2509页

学科分类:1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主  题:Hepatitis B vaccine Non-responders Intradermal vac 

摘      要:Hepatitis B virus(HBV) infection is a global health problem. It is estimated there are more than 2 billion individuals exposed to the virus and 250 million are chronically infected. Hepatitis B is the cause of more than 600000 annual deaths due to cirrhosis and hepatocellular carcinoma. An effective vaccine exists and preventative initiatives center around universal vaccination especially in those at highest risk. Effective vaccination algorithms have led to a significant decline in the development of new infections and its devastating consequences. The vaccine is administered intramuscularly in three doses, with 95% showing long lasting serologic immunity. An additional fourth dose or a repeated higher dose three course regimen is given to those that fail to show immunity. Despite these additional regimens, some remain vulnerable to hepatitis B and are deemed nonresponders. Individuals with chronic disease states such as kidney disease, liver disease, diabetes mellitus, as well as those with a genetic predisposition, and those on immunomodulation therapy, have the highest likelihood of non-response. Various strategies have been developed to elicit an immune response in these individuals. These include increased vaccination dose, intradermal administration, alternative adjuvants, alternative routes of administration, co-administration with other vaccines, and other novel therapies. These alternative strategies can show improved response and lasting immunity. In summary, HBV vaccination is a major advance of modern medicine and all individuals at risk should be sought and vaccinated with subsequent adequate titers demonstrated.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分